Korean J Hematol.  2012 Jun;47(2):85-86. 10.5045/kjh.2012.47.2.85.

Is radioimmunotherapy a 'magic bullet'?

• Kim SH

• KMID: 2083598
• DOI: http://doi.org/10.5045/kjh.2012.47.2.85

Abstract

No abstract available.

MeSH Terms

Radioimmunotherapy

Figure

• 

  Fig. 1 Radioimmunotherapy (RIT) using monoclonal antibodies labeled with a radioisotope emitting gamma- or beta- rays.

Reference

1. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med. 2011. 84:391–407.

2. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist. 2009. 14:Suppl 2. 41–51.

3. Jo JC, Yoon DH, Kim S, et al. Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. Korean J Hematol. 2012. 47:119–125.

4. Han EJ, Lee SE, Kim SH, et al. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol. 2011. 90:1075–1082.